ARCHIVES

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

This article is from The Cancer Letter archive.

Vol. 34 No. 7 | July 29, 2011

Download PDF Visit The Full Archive

Related Articles

Endostatin Enters Phase II Trial For Neuroendocrine Tumors.

December 14, 2001

Afinitor Tablet Doubles PFS; Lowers Progression Risk 65%

February 25, 2011

NCI Advisory Group, Other Cancer Meetings

April 29, 1983

Lung Cancer Studies Described by DCT, VA

May 9, 1975

Varmus Pools $13.4 M. To Fund Projects; NCI Gives $2.6 Mil.

December 9, 1994

DRCCA Board Oks Noncompetitive Contract Concepts

November 11, 1983